Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations
Ben-Ami, Tal; Kontny, Udo; Surun, Aurore; Brecht, Ines B.; Almaraz, Ricardo López; Dragomir, Monica; Pourtsidis, Apostolos; Casanova, Michela; Fresneau, Brice; Bisogno, Gianni; Schneider, Dominik T.; Reguerre, Yves; Bien, Ewa; Stachowicz-Stencel, Teresa; Österlundh, Gustaf; Wygoda, Marc; Janssens, Geert O.; Zsiros, József; Jehanno, Nina; Brisse, Herve J.; Gandola, Lorenza; Christiansen, Hans; Claude, Line; Ferrari, Andrea; Rodriguez-Galindo, Carlos; Orbach, Daniel
(2021) Pediatric Blood and Cancer, volume 68 Suppl 4, issue S4
(Article)
Abstract
Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC
... read more
developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5-flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN-β) for selected high-risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long-term treatment-related complications that affect most of the survivors.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: adolescent, children, nasopharyngeal carcinoma, radiotherapy, rare tumors, recommendations, Hematology, Oncology, Pediatrics, Perinatology, and Child Health, Journal Article
ISSN: 1545-5009
Publisher: Wiley-Liss Inc.
Note: Funding Information: The authors have no financial relationships relevant to this article to disclose. The French FRACTURE group is supported by “SFCE ‐ Enfants Cancers et Santé.” The German STEP Registry is supported by the German Childhood Cancer Foundation. The Italian TREP Registry has been partially supported by Fondazione Giovanni Celeghin, ONLUS. Funding Information: This publication is part of the EU PARTNER project (ERN‐PAEDCAN Partner Paediatric Rare Tumours Network ‐ European Registry), which has received funding from the European Union's Health Programme (2014–2020) (third Health Programme Call: HP‐PJ‐06‐2016: Rare diseases ‐ support for New Registries; CHAFEA Grant Number: 777336). Publisher Copyright: © 2021 Wiley Periodicals LLC © 2021 Wiley Periodicals LLC.
(Peer reviewed)